Department of Pharmacy, Seattle Children's Hospital, Washington.
Department of Pediatrics, Division of Infectious Diseases, University of Washington School of Medicine, Seattle Children's Hospital, Washington.
J Pediatric Infect Dis Soc. 2019 Sep 25;8(4):365-367. doi: 10.1093/jpids/piy094.
Limited data exist on intravenous (IV) posaconazole dosing and the risk for hepatotoxicity it confers to children. In this study, we evaluated dosing and resulting trough levels in 10 pediatric patients on IV posaconazole. A therapeutic level in these patients was achieved 95% of the time. We found a median minimum effective dose of 6.55 mg/kg of body weight. No correlation was found between the duration or posaconazole trough level and an increased alanine transaminase level.
关于静脉注射（IV）泊沙康唑的剂量及其对儿童的肝毒性风险，目前数据有限。在这项研究中，我们评估了 10 名接受 IV 泊沙康唑治疗的儿科患者的剂量和谷浓度。这些患者的治疗水平 95%的时间都能达到。我们发现中位最小有效剂量为 6.55mg/kg 体重。未发现泊沙康唑谷浓度或持续时间与丙氨酸氨基转移酶水平升高之间存在相关性。
